PURPOSE: Ansaplastic thyroid cancer (ATC) is one of the most lethal malignancies, but the carcinogenic mechanism of ATC has not been clarified. Recently, we performed a cDNA microarray analysis and identified transmembrane protein 34 (TMEM34) that down-regulated in anaplastic thyroid cancer cell lines (ACL)s as compared to normal thyroid tissues. METHODS: To investigate the role of TMEM34 in ATC carcinogenesis, we examined expression levels of TMEM34 in ACLs as well as differentiated thyroid cancers (DTC)s and normal human tissues. To explore the effect of TMEM34 in ATC development, cell-growth assays with KTA2 cells were performed. RESULTS: Expression of TMEM34 was down-regulated in all 11 ACLs, as compared to either normal thyroid tissues or cell lines derived from papillary or follicular thyroid cancers. TMEM34 was expressed ubiquitously in normal human tissues tested. Transfection of TMEM34 into KTA2 cells led to inhibition of cell growth. CONCLUSIONS: Our findings suggest that TMEM34 might be a tumor suppressor gene, associated with the development of ATC from DTC.
PURPOSE:Ansaplastic thyroid cancer (ATC) is one of the most lethal malignancies, but the carcinogenic mechanism of ATC has not been clarified. Recently, we performed a cDNA microarray analysis and identified transmembrane protein 34 (TMEM34) that down-regulated in anaplastic thyroid cancer cell lines (ACL)s as compared to normal thyroid tissues. METHODS: To investigate the role of TMEM34 in ATC carcinogenesis, we examined expression levels of TMEM34 in ACLs as well as differentiated thyroid cancers (DTC)s and normal human tissues. To explore the effect of TMEM34 in ATC development, cell-growth assays with KTA2 cells were performed. RESULTS: Expression of TMEM34 was down-regulated in all 11 ACLs, as compared to either normal thyroid tissues or cell lines derived from papillary or follicular thyroid cancers. TMEM34 was expressed ubiquitously in normal human tissues tested. Transfection of TMEM34 into KTA2 cells led to inhibition of cell growth. CONCLUSIONS: Our findings suggest that TMEM34 might be a tumor suppressor gene, associated with the development of ATC from DTC.
Authors: F Moretti; A Farsetti; S Soddu; S Misiti; M Crescenzi; S Filetti; M Andreoli; A Sacchi; A Pontecorvi Journal: Oncogene Date: 1997-02-13 Impact factor: 9.867
Authors: Y Yu; C Zhang; G Zhou; S Wu; X Qu; H Wei; G Xing; C Dong; Y Zhai; J Wan; S Ouyang; L Li; S Zhang; K Zhou; Y Zhang; C Wu; F He Journal: Genome Res Date: 2001-08 Impact factor: 9.043
Authors: Sam M Wiseman; Thom R Loree; Nestor R Rigual; Wesley L Hicks; Wade G Douglas; Garth R Anderson; Daniel L Stoler Journal: Head Neck Date: 2003-08 Impact factor: 3.147
Authors: Jie Hu; Chengchuan Jiang; Ho-Keung Ng; Jesse C S Pang; Carol Y K Tong; Shangqun Chen Journal: Chin Med J (Engl) Date: 2003-04 Impact factor: 2.628
Authors: M Onda; J Akaishi; S Asaka; J Okamoto; S Miyamoto; K Mizutani; A Yoshida; K Ito; M Emi Journal: Br J Cancer Date: 2005-06-20 Impact factor: 7.640
Authors: Frederikke G Malinovsky; Peter Brodersen; Berthe Katrine Fiil; Lea Vig McKinney; Stephan Thorgrimsen; Martina Beck; H Bjørn Nielsen; Stefano Pietra; Cyril Zipfel; Silke Robatzek; Morten Petersen; Daniel Hofius; John Mundy Journal: PLoS One Date: 2010-09-07 Impact factor: 3.240
Authors: Martha R C Bhattacharya; Stefanie Geisler; Sara K Pittman; Ryan A Doan; Conrad C Weihl; Jeffrey Milbrandt; Aaron DiAntonio Journal: J Neurosci Date: 2016-04-27 Impact factor: 6.167
Authors: Erik M K Rasmussen; Kristine L Seier; Ingrid K Pedersen; Claus Kreibich; Gro V Amdam; Daniel Münch; John Arne Dahl Journal: Sci Rep Date: 2021-09-27 Impact factor: 4.379